Perkins Adelene Q's Form 4 filing
Infinity Pharmaceuticals, Inc. (INFI) · filed Sep 12, 2023
- Accession no.
- 0000899243-23-018762
- Filed
- Sep 12, 2023, 6:20 PM ET
- Trade date
- Sep 9-12, 2023
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $28.7K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Perkins Adelene QCIK 0001375124 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2023 | Common Stock | MOption exerciseAcquired | +768,133 | – | – | 1,585,487 | Direct | |
| Sep 12, 2023 | Common Stock | SSaleDisposed | −410,196 | $0.07 | −$28,713.72 | 1,175,291 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2023 | Common Stock | MOption exerciseDisposed | −768,133 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.